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We have designed and synthesized a series of small peptides containing a perfluoroalkyl ketone group at 
the C-terminal position of the angiotensin I sequence as inhibitors of human renin. From this series of com- 
pounds, $ and 10 showed strong inhibition of human renin (ICso = 3 x 10-9, 7 x 10-9 M, respectively). Com- 
pound 10 did not inhibit pepsin and cathepsin D at 10 -4 M. Comparison of the ICso of compound 8 and 
compound 11 (8.7 × 10 -7 M) demonstrated the marked effect of the perfluoropropyl group on the potency 
of inhibition on renin, presumably due to the strong electron-withdrawing effect causing the ketone in 8 
to exist predominantly asthe hydrate - thus mimicking the tetrahedral transition state during hydrolysis 
of the scissile Leu~°-Val n amide bond. 
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1. INTRODUCTION 
Renin is the enzyme which cleaves a decapeptide 
fragment from the N-terminal portion of angioten- 
sinogen, thereby initiating the renin-angiotensino- 
gen-converting enzyme cascade. The important 
role played by the renin-angiotensin system (RAS) 
[1] in the etiology of some forms of cardiovascular 
disease has recently been demonstrated by the suc- 
cessful development of ACE inhibitors as clinically 
useful agents for the treatment of hypertension 
and congestive heart failure [2]. 
Intense research efforts to block the RAS at the 
first catalytic step have resulted in a continued 
search to discover an orally active renin inhibitor 
[3]. During the past several years a large number of 
structurally diverse peptide analogs have been 
described as renin inhibitors. Kokubu et al. [4] 
reported that small peptidic aldehydes at the C- 
terminal position of angiotensin I are potent in- 
hibitors of human renin, while Szelke et al. were 
the first to describe renin inhibitors containing a 
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reduced amide [5] and a hydroxyethylene isostere 
[6] at the scissile Leul°-Val tl amide bond. Renin 
inhibitors incorporating the amino acid statine [7] 
and more recently difluorostatine and difluoro- 
statone [8] have also been described. The high level 
of interest in preparing fluoro ketone analogs as 
inhibitors of proteolytic enzymes [8-10] prompted 
us to report our work in this area. Here, we 
describe a series of small peptides containing a per- 
fluoroalkyl ketone moiety incorporated at the C- 
terminal position of angiotensin I. The inhibitor 
potency of these compounds against human renin 
and their specificity against other aspartic pro- 
teinases are also presented. 
2. MATERIALS AND METHODS 
2.1. Renin assay 
Purified human renal renin [11] was assayed 
utilizing pure human angiotensinogen [12] at pH 
6.0 in maleate buffer. Test compounds were 
dissolved in DMSO and diluted so that prior to ad- 
dition to the assay system the solutions were 10O7o 
in DMSO and 0.5°70 in BSA. The final incubation 
mixture (100/zl) contained 0.135 M maleate buffer 
(pH 6.0), 3 mM EDTA, 1.4 mM PMSF, 0.21/zM 
Published by Elsevier Science Publishers B. E (Biomedical Division) 
00145793/87/$3.50 © 1987 Federation of European Biochemical Societies 299 
Volume 220, number 2 FEBS LETTERS August 1987 
angiotensinogen, 0 .24mGU renin [13], 0.44°7o 
BSA, 1070 DMSO. At least 3 different concentra- 
tions of inhibitor which bracketed the concentra- 
tion causing 5007o inhibition (ICso) were prein- 
cubated with renin for 5.0 min at 37°C, then sub- 
strate was added and the incubation was allowed to 
proceed for 10.0 min. The reaction was stopped by 
freezing the solution in a methanol-dry ice bath, 
and after thawing at 4°C an aliquot was analyzed 
for angiotensin I by radioimmunoassay utilizing a 
commercial kit (NEN Research). The percent in- 
hibition of the reaction was determined and the 
ICso was calculated by regression analysis. The 
reaction time of 10.0 min was on the linear portion 
of the incubation time vs angiotensin I generation 
curve, and at the highest concentration tested none 
of the compounds cross-reacted with the antibody 
to angiotensin I. The presence of 1 07o DMSO in the 
final incubation mixture caused no statistically 
significant effect on the renin activity. 
2.2. Pepsin and cathepsin D assays 
Porcine pepsin (Sigma) and bovine cathepsin D 
(Sigma) activities were assessed by the hydrolysis 
of hemoglobin at pH 1.9 and 3.1, respectively, at 
37°C, and measurement of the absorbance at 
280 nm of the supernatant after precipitation with 
trichloroacetic acid [14]. 
Table 1 
2.3. Chemical synthesis 
The compounds described in this study were syn- 
thesized by the following methods: Boc-L-amino 
aldehyde was condensed with perfluoroethyl [15] 
or perfluoropropyl lithium generated in situ by the 
addition of methyllithium (complexed with lithium 
bromide) to the corresponding perfluoroalkyl 
iodide at - 78°C. The resulting Boc-fluoro alcohol 
was deprotected and coupled to Boc-Phe-His-OH 
or other dipeptides to give the precursor to the 
fluoro ketones. Oxidation of the fluoro alcohols to 
the final fluoro ketone products was performed 
with the oxidizing agent Dess-Martin periodinane 
[16]. Complete details of the chemical syntheses 
will be reported elsewhere. 
3. RESULTS AND DISCUSSION 
The small peptide analogs containing the per- 
fluoroalkyl ketone functionality and their precur- 
sor alcohols that were prepared in this study, along 
with the corresponding ICso values against human 
renin, are shown in table 1. We have reasoned that 
the ketones, because of the strong electron-with- 
drawing effect of the perfluoroalkyl group, would 
exist predominantly in the hydrated form as shown 
in the following equation. This hydrated form of 
the ketones (RI : isopropyl or cyclohexyl; 
Structure-activity relationship of perfluoroalkyl alcohols and ketones as inhibitors of human renin 
P3 P2 X I I  
BOC--AA 1 AA 2 NH~x x 
R2 
RI / 
PI 
No. AAI AA2 X a RI R2 IC50 (nM) 
1 Phe Leu H,OH isopropyl CF2CF2CF3 1200 
2 oL-Nal b Leu H,OH isopropyl CF2CF2CF3 150 
3 Phe Leu H,OH cyclohexyl CF2CF2CF3 52 
4 Phe His H,OH cyclohexyl CF2CF2CF3 27 
5 Phe Leu H,OH cyclohexyl CF2CF3 150 
6 Phe Leu O isopropyl CF2CF2CF3 120 
7 ct-Nal Leu O isopropyl CF2CF2CF3 23 
8 Phe Leu O cyclohexyl CF2CF2CF3 3 
9 Phe Leu O cyclohexyl CF2CF3 13 
l0 Phe His O cyclohexyl CF2CF2CF3 7 
11 Phe Leu O cyclohexyl CH2CH2CH3 870 
a All hydroxy compounds are a mixture of a/d-OH 
b c~-Naphthylalanine 
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H 0 HO OH 
P--N P--N 
- CF2R 2 + H20 CF2R 2 
R1 / RI / 
R2 = CF3 or CFzCF3; P = dipeptides) thus would 
mimic closely the tetrahedral transition state of the 
hydrolysis of the scissile Leul°-Val I1 amide bond 
of the angiotensinogen sequence. As a result, they 
should show tighter binding to renin than their 
precursor alcohols. As demonstrated by the results 
shown in table 1, all of the fluoro ketones were 
more potent inhibitors ( -10  x )  of human renin 
than the corresponding fluoro alcohols. Substitu- 
tion of the more lipophilic amino acid Leu for the 
His at the P2 site also maintained high inhibitory 
potency. The replacement of the isobutyl side 
chain of the Leu at the PI site with the more lipo- 
philic cyclohexylmethyl [7] side chain increased the 
potency by about 20-40-fold. Shortening the ter- 
minal perfluoropropyl group to a perfluoroethyl 
group led to a decrease in potency. In order to 
assess the effect of the perfluoroalkyl group on the 
inhibition of renin, compound 11 was synthesized 
for a direct comparison with compound 8. The on- 
ly difference between 8 and 11 was that the per- 
f luoropropyl group in 8 was replaced by an 
n-propyl group in 11. Compound 8 was 290-times 
more potent than compound 11, illustrating 
dramatically the proposed effect of the strong 
electron-withdrawing fluoroalkyl group on the 
degree of hydration of the ketone. 
We tested the effect of compound 10 on the 
other aspartic proteinases pepsin and cathepsin D. 
At 1 x 10 -4 M, compound 10 exhibited no inhibi- 
tion of either enzyme, thus demonstrating the 
marked specificity of compound 10 for renin. 
The small size of the perfluoroalkyl ketones 
described in this study and their relative stability as 
compared to peptidic aldehydes may provide a 
possibility for the development of orally active 
renin inhibitors. The in vivo activities of these 
compounds are currently under investigation. 
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